AIDS United’s annual conference brings HIV advocates to Washington amid growing threats to prevention, treatment, and funding.
CVS refused to cover Yeztugo, Gilead’s $28,000-a-year injectable PrEP, preventing patients from accessing the HIV prevention drug at no cost.
FDA approves PrEP drug. Lenacapavir is a twice-yearly HIV prevention shot more effective than daily pills.